润都股份：产品“缬沙坦氨氯地平片（I）”取得注册证

Group 1 - The core point of the article is that Rundu Co., Ltd. has received a drug registration certificate from the National Medical Products Administration for its product "Valsartan Amlodipine Tablets (I)" [1] - As of the first half of 2025, the revenue composition of Rundu Co., Ltd. is as follows: 56.18% from chemical drug formulation manufacturing, 42.61% from active pharmaceutical ingredient manufacturing, and 1.2% from other businesses [1] - The current market capitalization of Rundu Co., Ltd. is 4.2 billion yuan [1] Group 2 - The article mentions a competitive scenario where Nongfu Spring's green bottle launch has negatively impacted the market share of Yibao, which has dropped nearly 5 percentage points [1]